Physician profile
James Vincent Guarrera
NPI 1417998782
$1,021,884.37
in general payments reported to CMS, 2019-2025
10 companies · $237K in 2025
The $237K reported for 2025 was more than what 99% of Transplant Surgery providers received nationally (typical 2025 total: $423).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $136K · 2020: $123K · 2021: $102K · 2022: $119K · 2023: $155K · 2024: $150K · 2025: $237K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $523K · Travel and Lodging: $9,965 · Food and Beverage: $8,455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $523,184.03 |
| Travel and Lodging | $9,965.01 |
| Food and Beverage | $8,454.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organ Recovery Systems, INC. | $1,009,917.27 | 2019-2025 | |
| Csl Behring | $6,680.53 | 2019 | |
| Novartis Pharmaceuticals Corporation | $2,660.00 | 2020 | |
| Transmedics, INC. | $1,328.48 | 2025 | Organ Care System |
| Dilon Technologies, INC. | $669.04 | 2024-2025 | Hemoblast Bellows |
| Medistim USA, INC. | $272.83 | 2022 | |
| Davol INC. | $162.68 | 2025 | Phasix Mesh |
| Veloxis Pharmaceuticals, INC. | $123.50 | 2025 | Envarsus |
| Organox Ltd | $48.49 | 2025 | |
| Surgical Specialties Corporation (US), INC. (Dba Corza Medical) | $21.55 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Guarrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.